Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLTC | Q00610 | 13/20 | 0.78 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PARG | Q86W56 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14636859 | 0.89 | CLTC (0.77) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14636004 | 0.89 | CLTC (0.79) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14636718 | 0.88 | CLTC (0.78) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14636024 | 0.88 | CLTC (0.79) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14636558 | 0.88 | CLTC (0.79) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14635611 | 0.84 | CA12 (0.69) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14636234 | 0.83 | CLTC (0.78) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14557200 | 0.79 | CLTC (0.64) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL14635627 | 0.78 | CLTC (0.78) | CLTCCA12CA1CA2CA9 | |
| SCHEMBL7848586 | 0.77 | ERCC1 (0.62) | CLTCCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ABIVAX (FR) | 2023-05-11 | — | — | US | disclosed |
| WO-2013010218-A9 | INHIBITION OF CLATHRIN | FREIE UNIVERSITÄT BERLIN (DE) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013010218-A1 | INHIBITION OF CLATHRIN | FREIE UNIVERSITÄT BERLIN (DE) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ACE, ACE2, SARS1 | CLTC 431/4885CA12 720/4885CA1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.